Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for hematological malignancies. Cord blood is an alternative stem cell source when no suitable related or unrelated adult donor is available. Compared with other stem cell sources, cord blood stem cells allow HLA incompatibility from 0 to 2 locus mismatches of HLA -A, -B and -DR because their immune tolerance suppresses graft rejection and severe GvHD. Cord blood transplantation (CBT) is often adopted for high risk diseases due to its easy and rapid availability. Chimerism analysis of peripheral blood or bone marrow post HSCT is one of the strategies used to detect residual host hematopoiesis or leukemic cells. Chimerism analysis with PCR using specific short tandem repeats (STRs) of the recipient and donor can assess chimerism status even if there is no sex mismatch. 1 Previous studies examined the relationships between chimerism post HSCT and prognosis. 2, 3 The early detection of mixed chimerism may be a predictive factor for relapse. In the present study, a lineage-specific chimerism analysis using STRs was performed at each time point post CBT. Since alloreactive T cells have a crucial role in the suppression of relapse post HSCT, we focused on the relationship between T-cell chimerism and relapse.
Data were obtained from six adult transplant centers affiliated with the Nagoya Blood and Marrow Transplantation Group. Patients who underwent allogeneic stem cell transplantation were enrolled in this prospective study to monitor the posttransplant chimerism status. In addition to basic clinical information prospectively collected for the chimerism analysis, patient-, disease-and transplant-related data as well as transplant outcome data were collected. Among those who were enrolled in this chimerism study, 78 patients who received cord blood transplantation (CBT) as the first hematopoietic stem cell transplantation were included. The Institutional Review Board of the Nagoya University Graduate School of Medicine approved this retrospective analysis. The post-transplant chimerism status of peripheral blood cells was assessed by STR analysis as previously described. 4, 5 Cord blood cells were collected from residual cells in the bag on day 0. The heparinized peripheral blood samples of the recipients were collected before, and at days 14, 28, 56 and 84 (+/ − 7 days) after the transplant. Granulocytes were obtained from precipitate by removing lysed cells after incubation in ammonium chloride buffer. MNCs were separated into three fractions using immunomagnetic beads; the CD56+ fraction (called the natural killer (NK) cell fraction), the CD56 − /CD3+ fraction (called the T-cell fraction), and the CD56À /CD3-fraction (called the other MNC fraction). Post-transplant donor-type chimerism of ⩾ 95% was defined as complete donor chimerism (CDC) and o 95% as mixed chimerism (MC). The primary end point was relapse after transplant according to the post-transplant chimerism status at days 28, 56 and 84. For analysis of cumulative incidence of relapse, cases that relapsed or died before the time points of chimerism analysis and cases with missing data were excluded from the analysis. Secondary end points were treatmentrelated mortality, overall survival (OS), the incidence of grades II-IV and grades III-IV acute GvHD and chronic GvHD.
Patient characteristics are detailed in Supplementary table 1. The median follow-up of survivors was 18 months (range 3-81). Neutrophil engraftment was achieved in 83% (95% confidence interval (CI), 73-90%) at day 42. Lineage-specific chimerism status is shown in Figure 1 . At day 28, 51 cases (85%) achieved T-cell CDC. The percentage of T-cell CDC increased to 86% at day 56 and 94% at day 84 among patients whose chimerism data were available. The T-cell chimerism status at days 28 and 84 did not have a significant impact on relapse post days 28 and 84 (19% in CDC vs 33% in MC, P = 0.43; 22% in CDC vs 50% in MC, P = 0.29, respectively) (Figures 2a, c) . Fifty-two cases were evaluated for relapse according to day 56 T-cell chimerism status. Among them, 45 cases achieved CDC and seven cases were MC status. Of these 52 patients, the 2-year cumulative incidences of relapse were 17% in CDC cases and 57% in MC cases (Figure 2b ). The relapse rate post day 56 was significantly higher in T-cell MC cases than in T-cell CDC cases (P = 0.016). Of the 45 patients in CDC at day 56, 23 cases had been in remission and the remaining 22 had relapsed disease status at the time of HSCT. Among seven patients in MC at day 56, four cases had been in remission and 3 cases had relapsed disease status at the time of HSCT. In multivariate analyses, T-cell MC at day 56 had a significantly higher risk of relapse (hazard ratio (HR) 20.9; 95%CI, 4.2-103.1; P o 0.001) along with female-sex recipient (HR 7.8; 95%CI, 1.8-34.9; P = 0.007) and high risk of disease (HR 5.0; 95%CI, 1.7-15.0; P = 0.004). Among seven patients who had T-cell MC at day 56, four subsequently relapsed within 1 year after SCT (median day 147, range 76-216) and three among them died due to disease progression. As for myeloid and NK cell lineages, there were no differences in cumulative incidences of relapse between MC and CDC at days 28, 56 and 84. The cumulative incidences of grades II-IV and III-IV acute GvHD were 26% (95% CI, 17-36%) and 5% (95%CI, 2-12%) at day 100. The 2-year cumulative incidence of chronic GvHD was 9% (95% CI, 4-17%). The development of acute and chronic GvHD showed no association with T-cell chimerism. The 2-year incidence of treatment-related mortality was 15% (95% CI, 8-24%). T-cell chimerism had no significant impact on treatment-related mortality. With a median follow-up of 18 months for survivors, the 2-year OS was 56% (95% CI, 43-67%). T-cell chimerism status did not affect OS.
Since T cells are mainly responsible for the graft-versusleukemia (GVL) effect, we herein focused on T-cell chimerism in relation to relapse post CBT. T-cell chimerism at day 56 was associated with subsequent disease relapse. Other studies have also shown the impact of T-cell chimerism rather than myeloid chimerism on disease relapse. 6, 7 The cumulative relapse rate was significantly higher in patients whose chimerism at day 56 was MC even though some of these cases achieved CDC at day 84. This result suggests that the GVL effect around day 56 is important for suppressing subsequent relapse, although we must be aware that the number of MC patients was small, and a heterogeneous population was included in this study for diagnosis, conditioning, and disease status at HSCT. In the present study, 76% of cases received myeloablative conditioning, which might influence the (b) Two-year cumulative incidences of relapse were 17 and 57% in patients with CDC (n = 45) and MC (n = 7), respectively, at day 56 (P = 0.016). (c) Two-year cumulative incidences of relapse were 22 and 50% in patients with CDC (n = 40) and MC (n = 2), respectively, at day 84 (P = 0.29).
high rate of CDC after transplantation. To assess GVL effect in relation to relapse, a study with non-myeloablative conditioning setting may provide good evidence because GVL is more important for the suppression of relapse in HSCT with nonmyeloablative conditioning. Chimerism-based immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusion was previously reported to have efficacy for suppression of relapse post HSCT. 8, 9 Since cord blood cannot provide donor lymphocyte infusion after transplantation, withdrawal of immunosuppression and pre-emptive chemotherapy may be beneficial in MC cases. Although no significant differences were observed in the occurrence of acute or chronic GvHD between T-cell CDC and MC in the present study, T-cell chimerism may reflect the function of allo-reactivity in not only GVL effect, but also GvHD. Previous studies showed that higher T-cell chimerism was associated with the occurrence of acute GvHD, [10] [11] [12] chronic GvHD 13 or both. 14 No patient whose T-cell chimerism at day 28 was MC developed grades II-IV acute GvHD in this study. It is suggested that minor residual recipient T cells might suppress GvHD. The low overall incidence of chronic GvHD in this study was consistent with previous findings on CBT. Increase in relapse based on day 56 T-cell chimerism did not translate into a significant effect on OS. It may be hypothesized that earlier therapeutic intervention according to T-cell MC at day 56 may prolong OS to some extent, although it is difficult to assess its effects because of the small number of patients in MC at day 56.
In conclusion, mixed T-cell chimerism at day 56 using STRs may be predictive of disease relapse post CBT. T-cell chimerism around day 56 may reflect the GVL effect. An analysis with a larger number of homogenous cases with the same disease status and conditioning is needed to assess the predictive ability for relapse and the efficacy of chimerism-based prophylactic immunotherapy or chemotherapy to suppress relapse of hematological malignancies post HSCT.
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